5 Live - Major conference takeways from experts in 5 minutes or less. Featuring new content from #ASCO20
Roy Herbst, MD, PhD, FACP, FASCO; Yale Cancer Center 5Live #ASCO20
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Ajay K. Nooka, MD, MPH, FACP; Emory Winship Cancer Institute 5Live #ASCO20
Key Insights on DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
Hope S. Rugo Professor of Medicine; Director, Breast Oncology and Clinical Trials Education; UCSF Comprehensive Cancer Center 5Live #ASCO20
"Key Insights on Alpelisib + fulvestrant in PIK3CA-mutated HR+/HER2– advanced BC previously treated with CDK 4/6 inhibitor + aromatase inhibitor (AI): BYLieve study results "
Lindsey Roeker, MD Memorial Sloan-Kettering Cancer Center 5Live #ASCO20
Key Insights on Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
Thomas Powles, MD, MRCP; Barts Cancer Center 5Live #ASCO20
Key insights on IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
David Siegel, MD, PhD
Summary of CAR T-cell Therapy. Updates from ASH 2019.
Andrew Evens, DO, MSc, FACP
Summary of Hodgkin lymphoma updates from SOHO 2019.
Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
Paolo Strati, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20
Key insights on Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
LEAD: Leadership, Empowerment and Development for Women in Oncology
Nina Shah, MD, Julie Vose, MD, MBA, and Julie Brahmer, MD, MSc
LEAD 2019 key highlights from the conference Co-Chairs
Debra Patt, MD, MPH, MBA
Summary of Session VI: Patient Management and Supportive Care in an Era of New Therapies from LEAD 2019
Lauren Byers, MD and Joyce O'Shaughnessy, MD
Key Highlights on Emerging Biomarkers Session
Shikha Jain, MD, FACP and Stephanie Graff, MD
Social Media Workshop Key Highlights
Linda Bosserman, MD, Jane Meisel, MD, and Leora Horn, MD, MSc, FRCPC
Summary of Session VII: Workshop Panel on Leaning Into Leadership Opportunities from LEAD 2019
Stephanie Graff, MD and Charu Aggarwal, MD, MPH
Summary of Session VII: Workshop Panel on Building Your Brand from LEAD 2019
Sandra Horning, MD
Key highlights from the LEAD 2019 conference
Barrett McBride, Rachna Shroff, MD, and Elizabeth Comen, MD
Resiliency Workshop Key Highlights
Alessandra Ferrajoli, MD & Arlene Siefker-Radtke, MD
Key Clinical Highlights in CLL and Bladder Cancer